Investors might want to bet on Bioventus (BVS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...

Bioventus (BVS) shares ended the last trading session 12.4% higher at $11.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...

Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago. These figures are ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Bioventus (BVS) is a stock that can certainly grab the attention ...

Canaccord Genuity has upgraded Biomedical Devices and Services company Bioventus Inc (NASDAQ:BVS), highlighting greater insight into the progress of the turnaround and plans for future investment and ...